UroGen Pharma
URGN
65 hedge funds and large institutions have $116M invested in UroGen Pharma in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 7 closing their positions.
725% more call options, than puts
Call options by funds: $875K | Put options by funds: $106K
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 64 → 65 (+1)
1% more capital invested
Capital invested by funds: $115M → $116M (+$626K)
2.98% less ownership
Funds ownership: 56.4% → 53.41% (-3%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.48M |
| 2 |
Morgan Stanley
New York
|
+$868K |
| 3 |
Jane Street
New York
|
+$781K |
| 4 |
Millennium Management
New York
|
+$713K |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$679K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$5.55M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.79M |
| 3 |
BlackRock
New York
|
-$596K |
| 4 |
WCM
Wildcat Capital Management
New York
|
-$345K |
| 5 |
E
Ergoteles
New York
|
-$342K |
URGN Hedge Fund Activity: Q1 2023 in Review
65 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2023, worth a combined $116M — up 0.54% from $115M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new URGN positions and 7 closed out — a net gain of 1 holder — while 21 added to existing stakes and 14 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.48M. The largest seller was Stonepine Capital Management, cutting an estimated $5.55M.
- 65 institutional investors held UroGen Pharma (URGN) as of Q1 2023, up from 64 in Q4 2022.
- Funds reported $116M of UroGen Pharma stock for Q1 2023, up 0.54% quarter-over-quarter.
- 8 funds opened new UroGen Pharma positions in Q1 2023 and 7 closed out, a net change of +1 holder.
- The largest UroGen Pharma buyer in Q1 2023 was Susquehanna International Group, an estimated $1.48M added.
- The largest UroGen Pharma seller in Q1 2023 was Stonepine Capital Management, an estimated $5.55M sold.
Based on aggregated 13F filings for Q1 2023.